Combination therapy with anti-HIV-1 antibodies maintains viral suppression

Pilar Mendoza, Henning Gruell, Lilian Nogueira, Joy A. Pai, Allison L. Butler, Katrina Millard, Clara Lehmann, Isabelle Suárez, Thiago Y. Oliveira, Julio C. C. Lorenzi, Yehuda Z. Cohen, Christoph Wyen, Tim Kümmerle, Theodora Karagounis, Ching-Lan Lu, Lisa Handl, Cecilia Unson-O’Brien, Roshni Patel, Carola Ruping, Maike Schlotz, Maggi Witmer-Pack, Irina Shimeliovich, Gisela Kremer, Eleonore Thomas, Kelly E. Seaton, Jill Horowitz, Anthony P. West, Pamela J. Bjorkman, Georgia D. Tomaras, Roy M. Gulick, Nico Pfeifer, Gerd Fätkenheuer, Michael S. Seaman, Florian Klein (), Marina Caskey () and Michel C. Nussenzweig ()
Additional contact information
Pilar Mendoza: The Rockefeller University
Henning Gruell: Institute of Virology, University Hospital Cologne
Lilian Nogueira: The Rockefeller University
Joy A. Pai: The Rockefeller University
Allison L. Butler: The Rockefeller University
Katrina Millard: The Rockefeller University
Clara Lehmann: University Hospital Cologne
Isabelle Suárez: University Hospital Cologne
Thiago Y. Oliveira: The Rockefeller University
Julio C. C. Lorenzi: The Rockefeller University
Yehuda Z. Cohen: The Rockefeller University
Christoph Wyen: University Hospital Cologne
Tim Kümmerle: University Hospital Cologne
Theodora Karagounis: The Rockefeller University
Ching-Lan Lu: The Rockefeller University
Lisa Handl: University of Tübingen
Cecilia Unson-O’Brien: The Rockefeller University
Roshni Patel: The Rockefeller University
Carola Ruping: Institute of Virology, University Hospital Cologne
Maike Schlotz: Institute of Virology, University Hospital Cologne
Maggi Witmer-Pack: The Rockefeller University
Irina Shimeliovich: The Rockefeller University
Gisela Kremer: University Hospital Cologne
Eleonore Thomas: University Hospital Cologne
Kelly E. Seaton: Duke University
Jill Horowitz: The Rockefeller University
Anthony P. West: California Institute of Technology
Pamela J. Bjorkman: California Institute of Technology
Georgia D. Tomaras: Duke University
Roy M. Gulick: Division of Infectious Diseases, Weill Cornell Medicine
Nico Pfeifer: University of Tübingen
Gerd Fätkenheuer: University Hospital Cologne
Michael S. Seaman: Beth Israel Deaconess Medical Center, Harvard Medical School
Florian Klein: Institute of Virology, University Hospital Cologne
Marina Caskey: The Rockefeller University
Michel C. Nussenzweig: The Rockefeller University

Nature, 2018, vol. 561, issue 7724, 479-484

Abstract: Abstract Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in which a combination of 3BNC117 and 10-1074, two potent monoclonal anti-HIV-1 broadly neutralizing antibodies that target independent sites on the HIV-1 envelope spike, was administered during analytical treatment interruption. Participants received three infusions of 30 mg kg−1 of each antibody at 0, 3 and 6 weeks. Infusions of the two antibodies were generally well-tolerated. The nine enrolled individuals with antibody-sensitive latent viral reservoirs maintained suppression for between 15 and more than 30 weeks (median of 21 weeks), and none developed viruses that were resistant to both antibodies. We conclude that the combination of the anti-HIV-1 monoclonal antibodies 3BNC117 and 10-1074 can maintain long-term suppression in the absence of antiretroviral therapy in individuals with antibody-sensitive viral reservoirs.

Keywords: Maintained Suppression; Analytical Treatment Interruption (ATI); University Hospital Cologne; Pseudovirions; Latent Reservoir (search for similar items in EconPapers)
Date: 2018
References: Add references at CitEc
Citations: View citations in EconPapers (5)

Downloads: (external link)
https://www.nature.com/articles/s41586-018-0531-2 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:561:y:2018:i:7724:d:10.1038_s41586-018-0531-2

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-018-0531-2

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().